597 related articles for article (PubMed ID: 32233755)
1. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Guo J; Huang Z; Lin L; Lv J
J Am Heart Assoc; 2020 Apr; 9(7):e016219. PubMed ID: 32233755
[No Abstract] [Full Text] [Related]
2. Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint.
Cappuccio FP; Siani A
Nutr Metab Cardiovasc Dis; 2020 Jul; 30(8):1227-1235. PubMed ID: 32595085
[TBL] [Abstract][Full Text] [Related]
3. [Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].
Huang W; Li T; Ling Y; Qian ZP; Zhang YY; Huang D; Xu SB; Liu XH; Xia L; Yang Y; Lu SH; Lu HZ
Zhonghua Nei Ke Za Zhi; 2020 Sep; 59(9):689-694. PubMed ID: 32838499
[No Abstract] [Full Text] [Related]
4. Update Alert 3: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Mackey K; Kansagara D; Vela K
Ann Intern Med; 2020 Oct; 173(7):130-131. PubMed ID: 32845705
[No Abstract] [Full Text] [Related]
5. Response to "COVID-19 and ACEI/ARB: Not Associated?".
Schiffrin EL; Flack JM; Ito S; Muntner P; Webb RC
Am J Hypertens; 2020 Aug; 33(8):789-790. PubMed ID: 32415836
[No Abstract] [Full Text] [Related]
6. COVID-19 and ACEI/ARB: Not Associated?
Hajra A; Bandyopadhyay D
Am J Hypertens; 2020 Aug; 33(8):788. PubMed ID: 32415832
[No Abstract] [Full Text] [Related]
7. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.
Diaz JH
J Travel Med; 2020 May; 27(3):. PubMed ID: 32186711
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
Gersh FL
Mayo Clin Proc; 2020 Jul; 95(7):1552-1553. PubMed ID: 32622456
[No Abstract] [Full Text] [Related]
9. Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Kansagara D; Mackey K; Vela K
Ann Intern Med; 2020 Aug; 173(3):W66. PubMed ID: 32584593
[No Abstract] [Full Text] [Related]
10. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
Pranata R; Permana H; Huang I; Lim MA; Soetedjo NNM; Supriyadi R; Soeroto AY; Alkatiri AA; Firman D; Lukito AA
Diabetes Metab Syndr; 2020; 14(5):983-990. PubMed ID: 32615377
[TBL] [Abstract][Full Text] [Related]
11. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.
Kai H; Kai M
Hypertens Res; 2020 Jul; 43(7):648-654. PubMed ID: 32341442
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19.
Bae DJ; Tehrani DM; Rabadia SV; Frost M; Parikh RV; Calfon-Press M; Aksoy O; Umar S; Ardehali R; Rabbani A; Bokhoor P; Nsair A; Currier J; Tobis J; Fonarow GC; Dave R; Rafique AM
Am J Cardiol; 2020 Oct; 132():150-157. PubMed ID: 32819683
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus.
Verdecchia P; Angeli F; Reboldi G
J Hypertens; 2020 Jun; 38(6):1190-1191. PubMed ID: 32371811
[No Abstract] [Full Text] [Related]
14. Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.
Vázquez-Cornejo E
Bol Med Hosp Infant Mex; 2020; 77(5):274-281. PubMed ID: 33064690
[TBL] [Abstract][Full Text] [Related]
15. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
Young MJ; Clyne CD; Chapman KE
J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970
[TBL] [Abstract][Full Text] [Related]
16. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.
Matsuzawa Y; Ogawa H; Kimura K; Konishi M; Kirigaya J; Fukui K; Tsukahara K; Shimizu H; Iwabuchi K; Yamada Y; Saka K; Takeuchi I; Hirano T; Tamura K
Hypertens Res; 2020 Nov; 43(11):1257-1266. PubMed ID: 32820236
[TBL] [Abstract][Full Text] [Related]
17. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.
Zhou F; Liu YM; Xie J; Li H; Lei F; Yang H; Qin JJ; Cai J; Zhang XJ; Wu B; Xia M; Xiang D; Yang C; Ma X; Xu Q; Lu Z; Lu H; Xia X; Wang D; Liao X; Peng G; Yang J; Huang X; Zhang BH; Yuan Y; Wei X; Liu PP; Wang Y; Zhang P; She ZG; Xia J; Li H
Hypertension; 2020 Aug; 76(2):e15-e17. PubMed ID: 32493070
[No Abstract] [Full Text] [Related]
18. Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
Mackey K; Kansagara D; Vela K
Ann Intern Med; 2020 Sep; 173(5):W87. PubMed ID: 32701362
[No Abstract] [Full Text] [Related]
19. Commentary on "angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic".
Ferrario CM
Diabetes Metab Syndr; 2020; 14(5):1401-1402. PubMed ID: 32755842
[No Abstract] [Full Text] [Related]
20. In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension.
Yuan Y; Liu D; Zeng S; Wang S; Xu S; Wang Y; Yu R; Gao Y; Li H; Feng X; Zhou N; Zhao C; Gao Q
J Infect; 2020 Nov; 81(5):816-846. PubMed ID: 32800800
[No Abstract] [Full Text] [Related]
[Next] [New Search]
